The odds of a continued Uptrend are 74%. The Moving Average Convergence Divergence (MACD) just turned positive.The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected. The Stochastic Indicator demonstrated that the ticker has stayed in the overbought zone for 8 days.

Citigroup Inc. reported its second quarter earnings that beat analysts’ expectations, on the back of trading revenues strength. The bank’s earnings for the three months ending June came in at 50 cents per share, topping the Street consensus forecast of 29 cents per share.However, the figure is down -72.6% from the year-ago quarter. Revenues rose +5.3% year-over-year to $19.77 billion, exceeding analysts' estimates of  $19.1 billion. Solid capital markets trading revenues added positively to the results.

JPMorgan Chase & Co.'s second quarter earnings came in higher than expected by analysts.However, the financial behemoth announced that it would suspend its share buyback program through to at least the end of September. JPMorgan’s net income for the three months ending in June was  $4.7 billion, or $1.38 per share, beating the Street estimate of $1.04 per share.

The bank also cut  its dividend as coronavirus pandemic continues to wreak havoc in the economy. Wells Fargo ‘s net loss for the quarter came in at -$2.4 billion, or -66 cents a share, compared to income of +$6.2 billion, or +$1.30 a share  in the year-ago quarter.The loss was steeper than -16 cents a share loss expected by analysts polled by FactSet. Revenue of $17.8 billion was lower than year-ago quarter’s $21.6 billion. Net interest income of $9.88 billion fell -$2.2 billion year-over-year.

Yee gave  the biopharmaceutical company a share-price target of $90. Last week, Moderna said it completed enrolling patients for a Phase II study of the vaccine candidate, mRNA-1273. Yee predicts that mRNA-1273 will have at least an emergency-use authorization by early next year. Moderna said that it’s on track to deliver 500 million doses per year, and possibly up to 1 billion doses per year, starting 2021. According to Tickeron, MRNA enters an Uptrend because Momentum Indicator exceeded the 0 level on July 09, 2020 This indicator signals that MRNA's price has momentum to move higher, since its current price moved above its price 14 days ago.

A number of companies have seen their stock prices soar as demand for their services or products increased due to people staying at home.Both companies are set to report second quarter earnings in the next few weeks and both companies are expected to show significant increases in earnings per share when compared to the previous year. Netflix is expected to report earnings results on July 16.

They cited what they believe is an  pandemic-driven dominance of digital sales. Citi analyst Jason Bazinet said that while his team anticipate total U.S. retail sales in 2022 to be 1% above 2019 levels ,they expect  e-commerce to increase 43% while brick-and-mortar retail to fall 4%.If that holds up, Amazon's prospect potentially gets boosted. Bazinet expects Amazon to have 43% of the domestic e-commerce market by 2022, up from 38% in 2019, and almost 7% of total U.S. retail sales by 2022, up from 4% last year. According to Tickeron, AMZN in +6.08% Uptrend, growing for three consecutive days on July 09, 2020 As a Bullish sign, keep an eye on this company's ticker for future growth.

The analyst affirmed buy rating on the stock. According to the Goldman analysts expectations, Netflix will report an addition of at least a net 12.5 million subscribers (vs. consensus estimates of  8.2 million) in the quarter."While management is likely to guide the third quarter conservatively given the first-half outperformance and the massive uncertainty in the current environment, we believe consensus estimates for the second half and beyond remain too low," Goldman analyst Heath Terry wrote. For the full year, Goldman projects Netflix to report paid subscriber net additions of 45.6 million (vs. the FactSet consensus estimate of 35.8 million). According to Tickeron, NFLX's price moved above its 50-day Moving Average on June 15, 2020 This price move indicates a change in the trend, and may be a buy signal for investors.

By analyzing market trends from the first wave, you can predict behavior for the second. Technology stocks have performed at historic levels this year, but the market is severely overbought.To compensate for that, look at performance during Q1 and Q2, the height of global Covid shutdowns.

SAP's preliminary report revealed Q2 results that were higher than analysts’ expectations. In the preliminary report (that comes ahead of a full Q2 report due on July 27),  SAP states that the software company’s  Q2 revenue rose +2% annually on a non-IFRS basis to €6.74 billion($7.62 billion).This means that SAP’s stock grew similarly to ORCL’s over the last 12 months. SAP's P/E Growth Rating (40) in the Packaged Software industry is in the same range as ORCL (55).

Walgreens Boots Alliance Inc. reported third quarter earnings that missed analysts' expectations.  The retail/wholesale pharmacy company’s adjusted earnings for the three months ending in May came in at 83 cents per share, falling short of the Street consensus estimate of $1.18 per share.In 21 of 29 cases where WBA's RSI Indicator exited the overbought zone, the price fell further within the following month.

Apple shares got a price target hike from Deutsche Bank analyst Jeriel Ong . Ong boosted his target on the iPhone maker’s share price to $400 from $380.He affirmed his buy rating. Although the analyst did caution about what he thinks is the stock price’s  overreaction to the positive data points over the past two months, he is optimistic on the company's fundamentals. Amid his confidence about the company, the downside risks that Ong indicated include a more prolonged second wave of covid-19, iPhone delays hurting the stock price(which investors appear to largely be looking through now, according to Ong), and lower spending in the second half of the year due to smaller wallets and higher unemployment. Nevertheless, Apple can “work from present levels” according to Ong. According to Tickeron, AAPL's Aroon indicator reaches into Uptrend on July 07, 2020 For traders, this could mean going long on the ticker or exploring call options in the next month.

Nikola  got a rating upgrade from J.P. Morgan . Analyst Paul Coster  boosted rating on the hybrid truck design/manufacturing company's shares to overweight from neutral.Coster  affirmed his price target at $45. According to Coster, after a 40% month-to-date decline in July, the stock is beginning to look attractive for long-term investors ahead of a "number of potential positive catalysts in coming weeks and months.

In 14 of 26 cases where NGHC's RSI indicator exited the overbought zone, the price fell further within the following month.The odds of a continued Downtrend are 54%. The Moving Average Convergence Divergence (MACD) crossed below the signal line.

Bank of America will report before the open two days later. You could lump these four stocks together with a few other companies and you would have the definition of “too big to fail”.It was used to describe financial institutions that were so big that the overall economy could come under pressure if one of them failed. Since that time the Treasury and the Federal Reserve have a system of tests that they call a "stress test" to measure different aspects of the bank to make sure we don't go through another financial crisis.

Regeneron   shares climbed Tuesday, following news of the company being awarded a $450 million contract with the U.S. government, for developing coronavirus treatment. The biotechnology company said that the contract will support it in boosting production of the REGN-COV2, conditional upon the success of clinical trials and Emergency Use Authorization or product approval from the Food and Drug Administration grants REGN-COV2 is involved in two different clinical trials for both the treatment and prevention of the COVID-19. Another biotech company Novavax  also received a government contract, worth $1.6 billion from the federal government, to complete late-stage development of its NVX‑CoV2373 Covid-19 vaccine candidate, and to begin large-scale manufacturing and delivery of the drug by next year. Tickeron's Comparison of Novavax, Inc. (NVAX) vs Regeneron Pharmaceuticals, Inc. (REGN) : [NVAX & REGN] are closely correlated. Both companies

Preliminary results are expected at the end of this month. According to Novavax, the $1.6 billion from Operation Warp Speed will help towards a more widespread phase 3 trial as well as support the company stockpile and build out a distribution network for the drug. Tickeron's AI-powered scorecard rates NVAX a BUY. NVAX's Aroon indicator reaches into Uptrend on July 06, 2020 For traders, this could mean going long on the ticker or exploring call options in the next month.The odds of a continued Uptrend are 78%. The Moving Average Convergence Divergence (MACD) just turned positive.

  According to Google, the A100 will soon support its Kubernetes Engine service, and its Cloud AI Platform. Nvidia has claimed that the A100 substantially outperforms its last flagship server GPU (the Tesla V100, launched in mid-2017) when it comes to running popular AI-related workload. Tickeron's AI-powered scorecard rates NVDA a STRONG BUY. NVDA's Aroon indicator reaches into Uptrend on July 06, 2020 For traders, this could mean going long on the ticker or exploring call options in the next month.In 342 of 398 cases where NVDA Aroon's Indicator entered an Uptrend, the price rose further within the following month.

" Tickeron's AI-powered scorecard rates RUN a STRONG BUY. RUN's Aroon indicator reaches into Uptrend on June 30, 2020 For traders, this could mean going long on the ticker or exploring call options in the next month.In 232 of 279 cases where RUN Aroon's Indicator entered an Uptrend, the price rose further within the following month.

Shares of Sina Corp.  surged +10% in premarket trading Monday, after the China-based online media company said that it received a buyout bid from New Wave. The buyout bid would value Sina at about $2.68 billion.In 34 of 43 cases where SINA's MACD histogram became positive, the price rose further within the following month.